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 Georgia Southern University 
Jiann-Ping Hsu College of Public Health
BIOS 7231 – Clinical Trial Methodology 
 Spring 2018 
 
 
 
 
 
 
 
Prerequisites:      BIOS 6541; BIOS 7534; or by permission of instructor 
VISTA Address:  Via  MyGeorgiaSouthern on GSU Home Page 
Catalog Description: Students are introduced to regulatory, scientific, statistical and 
practical aspects of methods inherent in design, monitoring and 
analysis of clinical trials.  Clinical trials in many areas of drug 
development are presented, discussed and critiqued. 
Required Textbook:  Clinical Trial Methodology by Karl E. Peace and Din Chen 
 Series: Chapman & Hall/CRC Biostatistics Series  
 Cat. #:  C9179 
 ISBN:  9781584889175 
 ISBN 10:  1584889179 
 Publication Date:  July 19, 2010  
 Number of Pages:  420   
 The course is presented using power points. Students are 
 provided copies of the power points on a Flash Drive. 
Secondary Texts: 
Chen D, Peace KE (2017): Clinical Trial Data Analysis using R and SAS; Chapman & 
Hall/CRC, Taylor and Francis Group; ISBN:  978-1-4987-7982-4 
Instructor: Karl E. Peace 
Office: Hendrix Hall #1005 
Phone: 912-478-7905
E-Mail Address: kepeace@georgiasouthern.edu  or peacekarl@frontier.com
Office Hours: Wednesday – 3:00 PM – 5:00 PM
And – By appointment, any time via email & WebEx Software
Web Page: http://www.georgiasouthern.edu/~kepeace/
Class Meets: Wednesday – 5:00 PM-to-7:45 PM via combination of in class lectures and
electronic virtual classroom lectures via WebEx Software
-- Course schedules can be found at: http://www.collegesource.org/displayinfo/catalink.asp -- 
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Chen D, Peace KE (2010): Clinical Trial Data Analysis using R; Chapman & Hall/CRC, Taylor 
and Francis Group; ISBN:  978-1-4398-4020-7 
Chen, D, Peace KE (2013): Applied Meta-Analysis using R. Chapman & Hall/CRC, Taylor and 
Francis Group; 13: 978-1-4665-0599-5; May 2013. 
Chen D, Sun J, Peace KE [Editors and Author contributors] (2012): Interval-Censored Time-to-
Event Data: Methods and Applications"; Chapman & Hall/CRC, 
Taylor and Francis Group; Published July 2012. 
Peace, K. E. [Editor and Author contributor] (2008): Design and Analysis of Clinical Trials with 
Time to Event Endpoints; Chapman & Hall/CRC Taylor and Francis 
Group; Boca, ISBN 978-1-4200-6639-5. 
Peace, K. E. [Editor and Author contributor] (1992): Biopharmaceutical Sequential Statistical 
Applications. Marcel Dekker, Inc., New York, ISBN 0-8247-8628-9. 
Peace, K. E. [Editor and Author contributor] (1990): Statistical Issues in Pharmaceutical Drug 
Development.  Marcel Dekker, Inc., New York, ISBN 0-8247-8290-9. 
Peace, K.E. [Editor and author contributor] (1988): Biopharmaceutical Statistics in Drug 
Development. Marcel Dekker, Inc., New York, ISBN 0-8247-7798-0. 
 
Biostatistics Student Learning Outcomes (BSLO): 
 
Cross-cutting: 
 
1. Demonstrate proficiency and effectiveness in the communication of core public health 
principles and practices, both oral and written. 
2. Demonstrate proficiency in the integration of the core public health disciplines 
(Biostatistics, Epidemiology, Environmental Health, Health Policy/Management, and 
Social/Behavioral Science) in practice and research. 
3. Demonstrate proficiency in problem solving, critical thinking, and public health 
leadership. 
 
MPH Biostatistics Concentration:  
 
1. Provide  the  biostatistica l components of the  design of a public health or biomedica l 
experiment by:  clarifying the  rese arch objectives or questions; de termining data and 
endpoints to be  co llected appropriate  for the  objectives; translating the  objectives 
into biostatis tica l questions via hypothesis te sting or confidence  interval 
frameworks; de termining the  appropriate  sa mple  size ; and writing the  statis tica l 
analysis se ction of the  experiment. 
2. Apply appropriate  statistica l analysis methods using SAS to analyze  both ca tegorica l 
and quantitative  data. 
3. Deve lop written and oral reports to communicate  e ffective ly to rese arch investigators 
pivotal aspects of a study, including its design, objectives,  data, analysis methods,  
resu lts,  and conclusions ensuring that resu lts and conclusions are valid and reliable  
and address the  rese arch objectives.  
4. Create  a co llaborative  environment for working on written and oral reports and 
deve loping critica l thinking skills . 
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5. Describe  key conce pts and theory underlying biostatistica l methodology use d in 
probability and inferential, analytica l, and descriptive  statistics.  
 
Course Objectives: 
1. Translate public health and biomedical research objectives into statistical hypotheses 
(BSLO 1, 3, 4, 5) 
2. Design public health and biomedical research clinical trials (BSLO 1, 3, 4, 5)   
3. Develop Statistical Analysis Sections for public health and biomedical research Protocols 
(BSLO 1, 2, 3, 4, 5) 
4. Explain the requirements for good protocol development for public health and biomedical 
research clinical trials (BSLO 1, 2, 3, 4, 5) 
5. Apply common statistical descriptive and inferential analysis methods to data collected in 
public health and biomedical research clinical trials (BSLO 1, 2, 3, 4, 5) 
6. Describe methodological alternatives to commonly used statistical methods used in 
public health and biomedical research clinical trials when analysis assumptions are not 
met (BSLO 2, 3, 5) 
7. Interpret results of statistical analyses of data collected from public health and biomedical 
clinical trials (BSLO 1, 2, 3, 4, 5) 
8. Develop written and oral presentations based on statistical analyses of public health and 
biomedical research clinical trials, for both public health professionals and educated lay 
audiences (BSLO 1, 2, 3, 4, 5) 
9. Identify key federal regulation ‘governing’ the conduct of clinical trials (BSLO 1, 3, 5) 
10. Explain the importance of the numbers of patients in clinical trials (BSLO 1, 2, 3, 4, 5)   
11. Explain the importance of monitoring adverse experiences in clinical trials (BSLO 1, 2, 
3, 5) 
12. Describe methods for monitoring adverse experiences in clinical trials (BSLO 1, 2, 3, 5) 
13. Explain how data from multicentre clinical trials may be ‘pooled’ (BSLO 1, 2, 3, 5) 
14. Describe the issues in group sequential clinical trials (BSLO 1, 2, 3, 5) 
 
Instructional Methods: Class meetings will be a combination of lecture and class discussion in 
a blended format (In classroom, and virtual classroom via WebES in real time). Lectures for 
classes conducted via WebEX will be recorded so that students can replay them as a way of 
review.  After each class, students are expected to send to Dr. Peace 1 – 2 questions about 
material covered in the class.  The questions and their answers will be compiled into a Word 
document and sent to students before the next class.  The questions and their answers will be 
discussed by Dr. Peace at the beginning of the next class.  Homework assignments, class 
participation and the final examination constitute the basis of student grades.   Students are 
expected to make use of office hours (in office or via WebEX) and email contact to discuss 
concepts or difficulties they may have. In addition, they may seek the assistance of the GA. 
 
Daily Study Log:  Students are required to keep a daily computerized study log.  The study log 
should have a column for the date, a column to identify topic of study, a column to identify the 
time of beginning study, a column to identify the ending time of study, and a column to identify 
the amount of time spent in studying the topic. 
 
 
Final Examination:   April 27, 2018 Last day of classes   
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                                    April 30- May 04, 2018 Final exams 
                                     
            Grading: Weighting of assignments for purposes of grading will be as follows: 
 
 Final Exam (objectives 1-14, integrated)……………60% 
 Assignment (objectives 1-14, individually)……. …..30% 
                                          Class Participation (objectives 1-14, individually)…10% 
               ____ 
 Total Possible                     100% 
    
                                          The following point scale will be utilized in grading: 
 
90% - 100% A 
80% -   90% B 
70% -   80% C 
60% -   70% D 
  
                                          There are times when extraordinary circumstances occur (e.g., serious 
illness, death in the family, etc.).  In such circumstances, and/or if you 
need additional time to satisfactorily complete any course requirement, 
please consult with the instructor within a reasonable amount of time.   
 
Academic Misconduct: As a student registered at this University, it is expected that you will 
adhere to only the strictest standards of conduct.  It is recommended 
that you review the latest edition of the Student Conduct Code book, as 
well as the latest Undergraduate & Graduate Catalog to familiarize 
yourself with the University’s policies in this regard.  Your continued 
enrollment in this course is an implied contract between you and the 
instructor on this issue; from this point forward, it is assumed that you 
will conduct yourself appropriately. 
 
Academic integrity relates to the appropriate use of intellectual 
property.  The syllabus, lecture notes, and all materials presented 
and/or distributed during this course are protected by copyright law.  
Students are authorized to take notes in class, but that authorization 
extends only to making one set of notes for personal (and no other) 
use.  As such, students are not authorized to sell, license, commercially 
publish, distribute, transmit, display, or record notes in or from class 
without the express written permission of the instructor. 
 
Academic Handbook: Students are expected to abide by the Academic Handbook, located at 
http://students.georgiasouthern.edu/conduct/.  Your failure to comply 
with any part of this Handbook may be a violation and thus, you may 
receive an F in the course and/or be referred for disciplinary action. 
 
University Calendar: The University Calendar for the semester can be found at: 
http://students.georgiasouthern.edu/registrar/calendar.htm 
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Attendance Policy: Federal regulations require attendance be verified prior to distribution 
of financial aid allotments.  Students are expected to attend each 
class meeting. 
 
One Final Note: The contents of this syllabus are as complete and accurate as possible.  
The instructor reserves the right to make any changes necessary to the 
syllabus and course material.  The instructor will make every effort to 
inform students of changes as they occur.  It is the responsibility of the 
student to know what changes have been made in order to successfully 
complete the requirements of the course. 
 
Overview of the Content to be Covered During the Semester: 
 
Module I: An Overview of the Regulation of Pharmaceuticals  
Module II: An Overview of the Processes of Discovery, Basic Research, Clinical Development  
                    and Manufacturing in Pharmaceutical Development 
Module III: Biostatistical Aspects of Clinical Drug Development 
A. The Components of a Protocol  
B. Statistical Analysis Section of a Clinical Trial Protocol 
Module IV: Bioavailability & Bioequivalence of Pharmaceutical Formulations 
Module V: Interim Analyses: p-Value and Power Computations in Group Sequential Trials 
Module VI: Design & Analysis of Pivotal Clinical Trials to Assess the Efficacy of Drugs to  
                     Treat Panic Disorder 
Module VII: Design & Clinical Trials in the Prevention of NSAID Induced Gastric Ulceration 
Module VIII: Design & Analysis of Clinical Trials in the development of H2-Receptor  
                       Antagonist Drugs in the Optimal Treatment of Duodenal Ulcers 
Module XIX: Design & Analysis of Clinical Trials of Antianginal Drugs 
Module X: Enrichment Design & Analysis of Clinical Trials of Drugs to Treat Alzheimer’s  
                   disease 
Module XI: Analysis and Interpretation of Cancer Clinical Trials 
Module XII: Monitoring Adverse Experiences in Clinical Drug Development 
Module XIII: The Pooling of Data from Multicenter Clinical Trials 
Module XIV: The Importance of Numbers (of Patients) in Cancer Clinical Trials 
Module XV: Statistical Analysis of Dose Response Trials 
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Student Information (CTM Class): 
 
      Print Full Name                     email address                Pledge to spend enough time                 
                                                                                         to master material? Circle one. 
 
1. ________________          ________________            Yes          No       Undecided 
 
2. ________________          ________________            Yes          No       Undecided 
  
3. ________________          ________________            Yes          No       Undecided 
 
4. ________________          ________________            Yes          No       Undecided 
 
5. ________________          ________________            Yes          No       Undecided 
 
6. ________________          ________________            Yes          No       Undecided 
 
7. ________________          ________________            Yes          No       Undecided 
 
8. ________________          ________________            Yes          No       Undecided 
  
9. ________________          ________________            Yes          No       Undecided                   
 
10. ________________        ________________            Yes          No       Undecided 
 
11. ________________        ________________            Yes          No       Undecided 
 
12. ________________        ________________            Yes          No       Undecided 
 
